Sii Investments Inc. WI Sells 2,841 Shares of Celgene Co. (CELG)

Sii Investments Inc. WI reduced its stake in Celgene Co. (NASDAQ:CELG) by 41.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,968 shares of the biopharmaceutical company’s stock after selling 2,841 shares during the quarter. Sii Investments Inc. WI’s holdings in Celgene were worth $514,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of CELG. Neuberger Berman Group LLC raised its holdings in Celgene by 4.0% in the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after acquiring an additional 71,729 shares during the last quarter. Grisanti Capital Management LLC purchased a new position in Celgene in the 2nd quarter worth approximately $3,616,000. Lincoln Capital Corp raised its holdings in Celgene by 0.6% in the 2nd quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock worth $3,971,000 after acquiring an additional 185 shares during the last quarter. RiverPoint Capital Management LLC raised its holdings in Celgene by 3.1% in the 2nd quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock worth $15,799,000 after acquiring an additional 3,680 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in Celgene by 9.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock worth $83,344,000 after acquiring an additional 54,210 shares during the last quarter. 79.74% of the stock is currently owned by hedge funds and other institutional investors.

Celgene Co. (NASDAQ:CELG) traded down $0.39 during trading hours on Friday, hitting $104.36. The stock had a trading volume of 4,495,827 shares, compared to its average volume of 5,408,097. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The stock has a market cap of $82,471.45, a price-to-earnings ratio of 24.79, a price-to-earnings-growth ratio of 0.81 and a beta of 1.78. Celgene Co. has a 52-week low of $94.55 and a 52-week high of $147.17.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. Celgene’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.58 EPS. research analysts anticipate that Celgene Co. will post 6.68 earnings per share for the current year.

CELG has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated a “buy” rating and issued a $162.00 price objective on shares of Celgene in a report on Tuesday, September 26th. Robert W. Baird restated a “buy” rating and issued a $162.00 price objective on shares of Celgene in a report on Thursday, September 21st. Jefferies Group restated a “buy” rating and issued a $160.00 price objective on shares of Celgene in a report on Friday, September 15th. Mizuho boosted their price objective on shares of Celgene from $134.00 to $158.00 and gave the stock a “buy” rating in a report on Friday, September 15th. Finally, Bank of America reiterated a “buy” rating on shares of Celgene in a research note on Wednesday, September 13th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $132.63.

WARNING: “Sii Investments Inc. WI Sells 2,841 Shares of Celgene Co. (CELG)” was originally published by Week Herald and is the property of of Week Herald. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://weekherald.com/2017/12/30/sii-investments-inc-wi-has-514000-stake-in-celgene-corporation-celg.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply